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Abstract 
 
 
 A higher ratio of omega-6 (n-6) to omega-3 (n-3) long chain polyunsaturated 
fatty acids (LCPUFA) in breast tissue triglyceride (TG) has been correlated with 
increased risk of developing breast cancer.  Before dietary recommendations can be 
made regarding n-3 PUFAs in relation to breast cancer risk reduction, a noninvasive 
biomarker must be identified so that further research can be done in larger 
populations.   
 This pilot study compared LCPUFA intake to red blood cell (RBC) and 
plasma LCPUFAs in women at high risk for breast cancer.  Women were screened 
(n=260) at the University of Kansas Medical Center Breast Cancer Prevention Center 
high-risk breast clinic.  Eighty-six were eligible and of these 48 (58%) completed and 
returned the diet history questionnaire (DHQ). 
 The mean age of the subjects was 47 ± 9.9 years, and the mean body mass 
index (BMI) was 25 ± 4.4.  The mean 5-year Gail risk was 2.7 ± 2.2%.  Twenty-two 
(48%) of the subjects were premenopausal and 24 (52%) were postmenopausal.  
Fifteen (33%) were taking an n-3 PUFA supplement (fish oil or flaxseed).  Mean 
dietary intakes were 9.94 ± 4.9 g n-6/d and 1.26 ± 0.6 g n-3/d, with an n-6:n-3 ratio of 
approximately 9:1.  Total phospholipid (PL) n-6 in RBC and plasma was 27.74 ± 
3.44% and 33.92 ± 3.72%, respectively.  Total PL n-3 in RBC and plasma was 5.59 ± 
1.7% and 4.06 ± 1.19%, respectively. Plasma TG docasahexaenoic acid (DHA) was 
highly correlated with n-3 intake (r=0.53, p=<0.05).   
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 Women at the University of Kansas Medical Center Breast Cancer Prevention 
Center consume an n-6:n-3 LCPUFA ratio typical of the US population.  RBC PL n-
3s were significantly correlated to n-3, adding to the validity of both intake and 
biomarker assessment.   Additional analyses will address whether breast tissue TG n-
3 or n-6:n-3 ratio reflects a blood biomarker of n-3 or n-3:n-6 ratio. 
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Chapter 1 
 
Introduction 
 
As of 2006, there are over 2.5 million breast cancer survivors in the 
United States and according to the National Cancer Institute an estimated 
192,370 new cases of breast cancer were diagnosed in 2009. A higher ratio of 
omega-6 (n-6) to omega-3 (n-3) long chain polyunsaturated fatty acids 
(LCPUFA) in breast tissue triglycerides (TG) has been correlated with increased 
risk of developing breast cancer (1, 2).  Dietary interventions with n-3 PUFAs 
could reduce this ratio and potentially decrease the risk for breast cancer.  Red 
blood cell (RBC) phospholipid (PL) and plasma PL and TG are commonly used 
biomarkers for intake of LCPUFA.  In the European Prospective Investigation 
into Cancer and Nutrition (EPIC) project, usual fish intake correlated with 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in serum and 
low density lipoprotein PL and cholesteryl esters fractions demonstrating that 
these lipid fractions can be used as biomarkers for n-3 LCPUFA intake (3).  
Studies are lacking that quantify the usual LCPUFA intake in women at high 
risk for breast cancer or that compare RBC and plasma PL LCPUFA with fatty 
acid intake.   
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Justification for Further Investigation 
The Evidence Report on the effects of n-3 PUFAs on cancer, published 
by the U.S. Department of Health and Human Services in 2005, concluded that 
a beneficial effect of n-3 LCPUFAs on cancer risk in general does not exist but 
suggested that further research is indicated to determine if n-3 PUFAs are 
beneficial for specific types of cancer, such as breast cancer (4).  Before dietary 
recommendations can be made regarding n-3 PUFAs in relation to breast cancer 
risk reduction, a biomarker must be identified so that further research can be 
done in larger populations.  We conducted a pilot study to compare LCPUFA 
intake to RBCs and plasma LCPUFAs in women at high risk for breast cancer.  
The advantages of studying these relationships in women who are at risk for 
breast cancer are:  a) blood samples are available as part of routine screening for 
cell biomarkers and b) women who know they are at risk for breast cancer 
might be expected to have a more variable intake of n-3 LCPUFA than the 
general population of women.   
Statement of Purpose 
The present thesis explores the relationship between dietary fatty acid 
intake and fatty acids in plasma and RBC lipids.  The intent was to determine if, 
at usual intakes of n-3 LCPUFA, the RBC and plasma lipid LCPUFA are 
related to LCPUFA intake. 
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Research Questions 
Primary Questions: 
• What is the usual LCPUFA intake from food and supplements in women 
at high risk for breast cancer? 
• How does LCPUFA intake relate to the fatty acid profile in triglycerides 
and phospholipids in red blood cells and plasma? 
 
Secondary Questions: 
• What is the ratio of n-6/n-3 LCPUFA intake in women at high risk for 
breast cancer? 
• Is n-6/n-3 PUFA intake related to socioeconomic status in women at 
high risk for breast cancer? 
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Chapter 2 
 
Review of Literature 
 
Biochemical Studies 
Linoleic (18:2n-6) and alpha-linolenic (18:3n-3) acids are essential in 
the human diet because mammals lack the enzymes found in plants that can 
insert double bonds 3 (n-3 fatty acids) and 6 (n-6 fatty acids) carbons from the 
methyl end of the fatty acid.  Both linoleic acid and alpha-linolenic acids are 
found in vegetable oils but linoleic acid is more abundant in the US diet, 
because of the composition of the vegetable oils usually consumed.  Some foods 
that contain a relatively low ratio of linoleic to alpha-linolenic acid include 
walnuts, flaxseed and rapeseed (canola) oil.  A low ratio of dietary n-6:n-3 
PUFAs may protect against cancer (1, 5, 6).                             
The ratio of n-6 to n-3 PUFA in the Western diet is significantly higher 
than that of our ancestors who consumed a mostly plant-based diet.  Our 
ancestors consumed an n-6:n-3 PUFA ratio of approximately 1, and the current 
ratio is approximately 16.7:1 (7), with an average North American per capita 
intake of docasahexaenoic acid (C22:6 n-3, DHA) + eisocapentaenoic acid 
(C20:5 n-3, EPA) of 0.1-0.2 grams per day and alpha-linolenic acid (C18:3 n-3, 
ALA) 1.4 grams per day (8).  A high ratio of n-6:n-3 PUFA may contribute to 
chronic diseases such as inflammation, cardiovascular disease and cancer (4, 5, 
9).  Studies have suggested that n-3 PUFAs may offer protection against cancer, 
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while high intake of n-6 PUFA or a high ratio of n-6 to n-3 PUFA may promote 
cancer (5, 10-12).   
Terry, et al. proposed that n-3 PUFA decrease cancer risk by inhibiting 
conversion of the n-6 LCPUFA, arachidonic acid (AA, 20:4n-6) into 
eicosanoids via the cyclooxygenase-2 (COX-2) enzyme.  Eicosanoids include 
prostaglandins, hydroxyeicosatetraenoic acids (HETE) and leukotrienes, and 
eicosanoids may be involved in the carcinogenic process via several 
mechanisms (5, 10).  Eicosanoids are known to modify estrogen metabolism, 
increase oncogene expression, increase synthesis of cytotoxic cytokines, and 
modify tumor cell membrane compositions.  Tumor cells produce large 
quantities of prostaglandin E2 (PGE2), and PGE2  production is inhibited by n-3 
LCPUFAs (10).  It is estimated that the rate of conversion of alpha-linolenic 
acid (ALA, 18:3n-3) to EPA and DHA is low at 1-10% (13-15).  Based on the 
inefficiency of this conversion, it may be more beneficial to consume dietary 
EPA and DHA rather than ALA. 
N-3 PUFAs have been shown to decrease the risk of breast cancer via 
several possible mechanisms, including inhibition of angiogenesis (16-22); 
inhibition of tumorigenesis (23-27); mediation of transcription, mRNA stability 
and cellular differentiation (9, 28-31); antiproliferative effects (32); and 
promotion of apoptosis (33-35). 
Other studies have looked specifically at the role of DHA in breast 
cancer.  DHA has demonstrated a role in membrane stability, fluidity and 
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permeability (36).  DHA has also been shown to improve the response to 
cytotoxic agents in breast tumor cells (37) and may also induce cell apoptosis by 
influencing PPAR-gamma and p53 mechanisms  (33, 35). 
Animal studies  
Rodent studies have also demonstrated a potentially protective effect of 
n-3 LCPUFAs against breast cancer tumorigenesis (38-43).  The mechanism(s) 
of this association are not entirely understood.  The protection may be related to 
the anti-inflammatory properties of n-3 LCPUFAs (44).  Dietary flaxseed was 
shown to decrease tumor growth and metastasis in nude mice, while also down 
regulating insulin-like growth factor and epidermal growth factor receptor 
expression (40).  Similar results regarding decreased mammary tumor growth 
and metastasis were achieved in a study on female BALB/c mice fed high n-3 or 
high n-6 diets (41).  The results of another study showed that dietary DHA 
intake not only decreased the incidence of mammary tumorgenesis but also 
increased BRCA1 tumor suppressor protein by 60% (45).  Mice fed canola oil 
(high n-3) compared to corn oil (high n-6) had slower tumor growth (43).  
Several studies have suggested that n-6 LCPUFAs may promote mammary 
tumor development via the prostaglandin pathway (41, 46, 47).  N-3 PUFAs 
have also been shown to improve effectiveness of chemotherapy in estrogen-
dependent breast cancer and inhibit tumor development, while n-6 PUFAs may 
promote tumor development in breast cancer in rats and mice (6, 10, 46, 48).  
One study found that high n-3 fish oil and oleic acid inhibited lung 
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tumorigenesis and metastasis, but linoleic (18:2 n-6) and linolenic (18:3 n-3) did 
not (49).  This suggests that specific n-3 LCPUFAs may inhibit carcinogenesis, 
while other n-3 and n-6 LCPUFAs may promote it.  The ratio of n-3 to n-6 
LCPUFA also appears to be important(1, 5, 38). 
Epidemiological studies 
The uncertainty in cohort studies surrounding the relationship between 
dietary fat intake and breast cancer risk may be due in part to measurement error 
(50, 51).  Additionally, specific fatty acids are often not specified, and cooking 
methods (such as frying) which may alter the fat content are often not included 
in the analyses. 
The PUFA intakes in 56,000 French women were determined using 
validated French diet history questionnaires (52, 53).  Breast cancer risk was 
inversely associated with n-3 LCPUFA (EPA, DPA and DHA) intake in women 
with the highest intakes of n-6 (LA and AA) LCPUFA.  Risk also varied 
according to food source of alpha-linolenic acid (ALA).  For ALA sources of 
food, risk was inversely correlated with the intake of n-3 PUFA from fruits, 
vegetables and vegetable oils but was positively correlated with the intake of n-
3 PUFA from nut mixes (also highest intake of vitamin E).  The authors 
concluded that it is important to consider the food source of LCPUFA due to 
potential interactions between ALA and other food components such as 
antioxidants.   
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LCPUFA samples were analyzed from the buttock adipose tissue in 
breast cancer patients during the European Community Multicenter Study on 
Antioxidants, Myocardial Infarction, and Cancer (EURAMIC) breast cancer 
study (1991-1992) (53).  Neither n-3 nor n-6 PUFA alone was correlated with 
breast cancer risk; however, the ratio of n-6:n-3 PUFAs was inversely correlated 
with breast cancer risk in four out of the five centers. The results suggest that 
the ratio is more important than the individual family of fatty acids.  However, 
not all studies show an inverse relationship with n-3 LCPUFA intake. A study 
performed in Denmark, where fish consumed tends to be fatty fish (e.g. salmon, 
tuna, mackerel, sardines, and trout) concluded that higher total fish intake was 
positively associated with ER+ breast cancer (54, 55).  Higher intake of most 
sea fish is equivalent to higher intake of other things, which could be a 
confounder. 
Most, observational studies suggest that women with relatively lower 
intakes of n-3 PUFAs have higher risk of breast cancer (52, 53, 56-61).  
However, the observational studies have many limitations such as lack of 
characterization of the source and amount of n-3 LCPUFA and an absence of 
information about individual ratios of n-6:n-3 PUFA, antioxidant status, and 
single nucleotide polymorphisms (SNPs) of fatty acid desaturase enzymes that 
appear to influence LCPUFA (5).  For example, most observational studies 
assessed n-3 LCPUFA intake by asking about total fish consumption rather than 
species consumed and preparation methods even though it is well known that 
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EPA and DHA levels vary among fish species and some methods of preparation 
add considerable amounts of trans fatty acids that are associated with lower 
LCPUFA status (62, 63).   
In the EPIC study, total fish intake and types of fish consumed was quite 
variable between countries as well as among individuals from day to day (55).  
Such measurement error may account for conflicting epidemiological evidence 
regarding fat intake and breast cancer risk (64).  In the American Association of 
Retired Persons (AARP) Diet and Health Study dietary fat was correlated with 
breast cancer risk (65); however, in the Nurses’ Health Study it was not (66).  
Pooled analyses of cohort studies did not relate fat intake to breast cancer risk 
(10, 67).  Other types of fat, such as saturated fat, may be associated with breast 
cancer (68, 69), again demonstrating that different fatty acids have different 
roles in carcinogenesis (62, 70, 71). 
Questions have been raised regarding the timing of fat intake during the 
lifespan.  Several studies found no association between midlife fat intake and 
postmenopausal breast cancer (72, 73).  However, a nested case-control study 
within the Nurses’ Health Study cohort found that women with higher intakes of 
eggs, vegetable fat and fiber during adolescence had a lower risk of breast 
cancer, while butter consumption increased risk (74).  Another study found that 
women with a higher intake of animal fat during premenopausal years had a 
higher risk of breast cancer (75).  It is also noteworthy that breast cancer 
incidence is much lower in China and Japan than the United States (76), and 
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dietary factors have been possibly implicated.  Groups who have emigrated to 
the United States from China and Japan have greater breast cancer incidence 
rates than in their respective countries (77).  In a study among Japanese 
immigrants in Los Angeles County, breast cancer rates were lower in 
immigrants at a younger age, yet still higher than those in Japan, suggesting that 
age of dietary change may influence breast cancer risk. 
Case-control studies 
In general, case-control studies have found an association between 
saturated and trans-fatty acid intake and n-6 PUFA intake and increased risk of 
breast cancer (75, 78-80) and between intakes of n-3 PUFA, fish and olive oil 
and decreased risk of breast cancer (81-86). 
In a case-control study assessing n-3 and n-6 PUFAs in breast adipose 
tissue, samples were taken from the breasts of 241 women with invasive, 
nonmetastatic breast carcinoma and 88 women with benign breast disease (1).  
Results showed an inverse relationship between n-3 PUFA levels in the breast 
adipose tissue and breast cancer risk.  In another case-control study, fatty acid 
content of breast adipose tissue was used as a tissue biomarker n-3 and n-6 
LCPUFA status (6).  Levels of n-6 PUFAs were significantly higher in the cases 
than controls, and results once again suggest that a lower ratio of n-6:n-3 
PUFAs may decrease the risk of breast cancer.         
In a cohort from the Diet, Cancer and Health study, higher total intakes 
of fish (including fried, boiled, and processed) were correlated with a higher 
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incidence of ER+ breast cancer (54).  Questions have been raised about trans-
fatty acids added during cooking, but this variable was not measured in the 
Danish cohort.  In the Multi-Ethnic Study of Atherosclerosis, plasma PL EPA 
and DHA were associated with intake of non-fried fish when seafood groups 
were adjusted for; however, when seafood groups were not adjusted for, there 
was a 67% decrease in the correlation (63).  
Human intervention studies 
There are currently no published results from human intervention trials 
regarding intervention with n-3 LCPUFA in breast cancer prevention and 
treatment.  As of April 2010, there are four ongoing clinical trials in this area of 
research.  Much work is yet to be done regarding the safety and efficacy of n-3 
LCPUFA for breast cancer risk reduction(4).  NCT00114296 is a pilot study 
looking at the effects of n-3 PUFA supplementation on mammographic breast 
density in 80 women at high risk for developing breast cancer.  Secondary 
objectives are to determine effects of n-3 PUFA supplementation on atypia and 
breast cell proliferation, circulating hormone and growth factor levels, 
expression of estrogen-related proteins, plasma lipid peroxidation levels, and to 
correlate the modifying effect of lipid peroxidation-related genes with 
mammographic breast density.  The control group of patients receives a placebo 
for 12 months, and the experimental group of patients receives an unspecified 
amount of n-3 LCPUFA orally 3 times per day.  
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NCT00723398 is a randomized, open-label prevention trial investigating 
the effect of n-3 LCPUFA supplementation alone and in conjunction with 
antiestrogen therapy in 372 postmenopausal women.  There are 5 arms, with the 
first serving as the control.  In the second arm, patients receive 60 milligrams 
per day of the antiestrogen drug, Raloxifene for two years.  In the third arm, 
patients receive 30 milligrams per day of Raloxifene for two years.  In the 
fourth arm, patients receive 4 grams per day of Lovaza (1860 mg EPA, 1500 mg 
DHA) for two years.  And in the fifth arm, patients receive 30 milligrams per 
day of Raloxifene plus 4 grams per day of Lovaza.  The primary outcomes of 
the study are the individual and combined effects of the drug (Raloxifene) and 
n-3 LCPUFA (Lovaza).  The primary outcome measure is breast density.  
Secondary outcomes include markers of oxidative stress, estrogen metabolism, 
inflammation, and IGF-1 signaling.   
NCT00627276 is a phase II randomized, double-blind, placebo control 
trial looking at the effect of n-3 LCPUFA supplementation in 40 women newly 
diagnosed with ductal carcinoma in situ and/or atypical ductal hyperplasia.  
Blood, urine, nipple aspirate fluid, and tissue are analyzed at baseline and 
completion for genetic markers for breast cancer.  Blood samples are analyzed 
for breast cancer genetic markers by microarray analysis and RBC fatty acids. 
NCT00930527 is a phase II trial in which the investigators are studying 
the safety and efficacy of n-3 supplementation on aromatase inhibitor (AI) 
induced joint pain in 10 postmenopausal women who had ER+ breast cancer.  
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The subjects are receiving 4 g of an n-3 supplement per day for 3 weeks.  The 
primary outcome is change in serum free and total estradiol at 3 weeks, and the 
secondary outcome is change in frequency of analgesics consumed at 12 weeks.   
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Chapter 3 
 
Methods 
 
Design of Inquiry 
Women at high risk for breast cancer were recruited from the University 
of Kansas Breast Cancer Prevention Center (BCPC) High Risk Breast Clinic 
(HRBC).  Diet History Questionnaires (DHQ) were be administered to obtain 
LCPUFA intake, and blood samples were obtained for fatty acid analysis. 
Inclusion and Exclusion Criteria 
The subjects were 48 women seen in the HRBC who had been identified as 
at high-risk for breast cancer and according to the following criteria: 
• First-degree relative (i.e. mother, sister or daughter) who had a breast 
cancer diagnosis before the age of 60  
• Prior diagnosis of atypical hyperplasia carcinoma in situ determined by a 
breast biopsy  
• Previous node-negative breast cancer  
• Multiple second-degree relatives who had a breast cancer diagnosis with 
at least one diagnosis under the age of 50  
• Multiple breast biopsies  
• Breast density greater than 50%  
The following were exclusion criteria: 
• Breast implants  
• The use of a blood-thinning medication  
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o
 Coumadin, Heparin, Plavix, Lovenox  
• Taking a chemotherapy or chemopreventative  
o
 Tamoxifen (Nolvadex), Raloxifene (Evista), Letrozole (Femara) 
or Anastrozole (Arimidex) for a year or more  
• Currently enrolled in another trial 
Diet History Questionnaires 
The DHQ was obtained from the National Cancer Institute website and 
distributed to the patients as a hard copy or portable document format (PDF) 
(see appendix B).  The patients were asked to fill out the survey and return it to 
the investigators during clinic or in a pre-paid envelope.  The DHQ responses 
were entered into the DHQ database and analyzed for nutrient composition.  No 
interviewer was required.  The DHQ consists of 124 food items and includes 
information regarding portion size and dietary supplement usage.  It takes 
approximately one hour to complete the questionnaire.   
The DHQ was developed by the Risk Factor Monitoring and Methods 
Branch (RFMMB) of the National Cancer Institute (NCI) 
(http://riskfactor.cancer.gov/DHQ/).  It measures usual intakes based on 
responses concerning foods consumed during the course of the past 12 months.  
Developers utilized cognitive research to develop a questionnaire that is easy to 
use.  It has been validated to accurately reflect dietary intake by three separate 
studies (87-89).  These studies found response rates from 70-85%, which is not 
statistically different from shorter questionnaires.  The DHQ utilizes an 
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accompanying database for analysis of nutrients and food groups.  The nutrient 
information is based on the 1994-96 USDA Continuing Survey of Food Intake 
by Individuals (CSFII), which was used to establish which foods to include in 
the survey and portion sizes.  The DHQ was analyzed using Diet*Calc 
Software, developed by the NCI. 
Blood Samples  
Whole blood was drawn into 4 mL tubes containing 
ethylenediaminetetraacetic acid (EDTA) and was refrigerated for several hours 
prior to transport to the laboratory where it was analyzed.  The tubes were 
labeled with the patient’s HRBC identification number and the study for which 
it was used.  All samples were logged in a book at the HRBC and analysis 
laboratory.   
A modification of the method developed by Folch et al. was used to 
extract total lipids from breast tissue and blood with chloroform: methanol 2:1 
(v:v) as part of a parallel study (90).  The extract was separated into two phases 
and washed with KCl.  The upper lipid layer was discarded.  The lower 
chloroform layer was evaporated to dryness with nitrogen and redissolved in 
100 µL of dichloromethane.  Adsorption chromatography (silica gel G. 
Analtech) was used to separate the TG and PL in 80:20:1 hexane: diethyl ether: 
acetic acid.  The PL band was scraped from the plate and collected in a screw-
cap tube containing 1mL BF3.  The TG band was scraped and placed in a 
separate tube containing 0.25 mL BF3, 0.2 mL Benzene and 0.55 mL methanol.  
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The lipid class bands were heated at 100°C for 10 and 30 minutes, respectively.  
The tubes were cooled, and fatty acid methyl esters (FAMEs) were extracted 
into pentane.  Pentane was evaporated, and the sample redissolved in 
dichloromethane.  FAMEs were analyzed with one standard run (Supelco 37) in 
sets of 12 using the Varian 3900 GC and attached autoanalyzer, and 
composition gas liquid chromatography (GLC) was used to determine 
composition.  FAME was identified by comparing samples to relative retention 
times of a mixture of weighed standards, and the relative amount (expressed as 
a weight percentage of total fatty acids) was determined by dividing the area 
under the curve by the total area for all fatty acids.  Each GC run was evaluated 
and repeated if the sample appeared to be overloaded or have some other 
analytical problem.   
Subjects  
 A total of 260 women were screened through the University of Kansas 
Medical Center Breast Cancer Prevention Center high-risk breast clinic.  From 
those screened, 86 were eligible (174 excluded), and 48 completed and returned 
the DHQ (58% response rate). 
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260 women screened
86 women recruited
48 women completed
(56% DHQ response ra te)
174 not eligible
Exclusion Criter ia
•Breas t implants 
•Th e use of a blo od-thinning 
medication 
•Coumad in, Hep arin, 
Plavix, Lov enox 
•Takin g a chemo therapy o r 
ch emopreventative 
•Tamoxifen (No lvadex), 
Ralox ifene (Ev ista), 
Letro zole (Femara) or 
An as trozole (Arimidex) for 
a year or more 
•Currently enrolled in ano ther trial
Inclusion Criteria
•First-degree relative (i.e. moth er, 
sis ter o r daughter) who had  a 
breas t cancer diagnosis before the 
age of 60  
•Prior diagno sis of atyp ical 
hyp erplasia carcino ma in si tu 
determin ed by a breast  b iopsy 
•Previo us node-negativ e b reast 
can cer 
•Mult iple secon d-degree relatives 
wh o h ad a breas t cancer diagn osis 
with at least one diagnosis und er 
the age of 50  
•Mult iple breast  biopsies 
•Breas t d ensity greater than  50 % 
Consort Diagram
Figure 1.  Consort Diagram 
 
 
 
 
 
 
 
 
 
 
 
Statistical Analyses 
 The DHQ’s were analyzed using DietCalc software obtained from the 
National Cancer Institute (www.riskfactor.cancer.gov/DHQ).  Results were 
downloaded into a Microsoft Excel spreadsheet and merged with all other data.  
Means and standard deviations were calculated using Microsoft Excel, and 
correlations were performed using SPSS 17.0 software.  Significance was 
defined as p = ≤0.05.   
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Chapter 4 
Results 
Demographics 
 
The mean age of the subjects was 48 ± 10 years and the mean height and 
weight were 65 ± 2.4 cm and 67.7 ± 16.0 kg, respectively. BMI was 25 ± 4 
kg/m2.  Thirty-four percent of subjects were overweight (BMI 25-29.9 kg/m2) 
and 15% were obese (BMI≥30 kg/m2).  The mean 5-year Gail risk was 2.7 ± 
2.2%(91).  The Gail model uses an individual’s prior biopsies, menstruation 
onset age, first live birth age and first-degree relative breast cancer history to 
estimate 5-year breast cancer risk.  The Gail model has been validated for white 
women. 
  Twenty-three (48%) of the subjects were premenopausal and 25 (52%) 
were postmenopausal.  Nineteen (40%) were currently using hormonal therapy, 
26 (54%) had used hormonal therapy in the past, and 3 (6%) had never used 
hormonal therapy.  Forty-four (92%) of subjects had post-high school 
education.  Thirty-one (65%) subjects had an annual household income 
>$60,000.  Forty-two (88%) of subjects had a family history of breast cancer.  
Sixteen (33%) were taking a n-3 PUFA supplement (fish oil or flaxseed).  See 
table 1 for socio-demographic characteristics of subjects. 
 
 
 
 
  
20 
 
 
 
Table 1.  Socio-demographic characteristics of subjects. 
Characteristics Subjects (n=48) 
Age (years) 48 ± 10* 
Height (cm) 65.0 ± 2.4* 
Weight (kg) 67.7 ± 16.0* 
BMI (kg/m2) 25 ± 4* 
5-year Gail risk (%) 2.7 ± 2.2* 
Menopausal status 
   Premenopausal 
   Postmenopausal 
 
n=23 (48%) 
n=25 (52%) 
Hormonal therapy 
   Current 
   Past 
   Never 
 
n=19 (40%) 
n=26 (54%) 
n=3 (6%) 
College education 
   High school/GED 
   Vocational/technical school 
   Associate’s degree/some college 
   College 
   Graduate/professional school 
   Other 
 
n=2 (4%) 
n=0 (0%) 
n=7 (15%) 
n=21 (44%) 
n=16 (33%) 
n=2 (4%) 
Household annual income level 
   <$20,000 
   $20-40,000 
   $40-60,000 
   >$60,000 
   Declined to answer 
 
n=0 (0%) 
n=7 (15%) 
n=9 (19%) 
n=31 (65%) 
n=1 (2%) 
Family history of breast cancer n=42 (88%) 
Taking n-3 fatty acid supplement n=16 (33%) 
*Mean ± standard deviation  
Energy and Nutrient Intakes 
 Energy and nutrient intake was reported as 1415 ± 477 calories/day.  
Mean carbohydrate intake was 171.11 ± 65.2 g/d, and mean fiber intake was 
15.2 ± 7.2 g/d.  Mean protein and fat intakes were 59.8 ± 21.9 g/d and 51.2 ± 
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18.6 g/d, respectively.  Distribution of macronutrients as a percentage of 
calories was as follows: carbohydrate 49 ± 10%, protein 17 ± 3%, and fat 33 ± 
7%.  Mean saturated and trans fat intakes were 15.46 ± 5.63 g/d and 2.63 ± 1.13 
g/d, respectively.  Mean MUFA and PUFA intakes were 19.77 ± 7.6 g/d and 
12.04 ±5.49 g/d.  Mean LA and ARA intakes were 10.78 ±4.97 g/d and 0.08 ± 
0.04 g/d, with a total estimated n-6 intake of 10.86 ± 5.0 g/d.  Mean ALA, EPA, 
and DHA intakes were 0.98 ± 0.45 g/d, 0.03 ± 0.03 g/d, and 0.06 ± 0.06 g/d, 
with a total estimated dietary n-3 intake of 1.07 ± 0.51 g/d.  Mean estimated 
total n-3 intake, including supplements, was 1.27 ± 0.6 g/d. Table 2 depicts the 
distribution of macronutrient intake.  
 
Table 2 .  Distribution of macronutrients as a percentage of total calories. 
Macronutrients Study Subjects 
WWEIA  
2005-2006 
Females  
Ages 40-49(92) 
Acceptable 
Macronutrient 
Distribution 
Ranges (93) 
Carbohydrate 49 ± 10*% 48% 45-65% 
Protein 17 ± 3*% 17% 10-35% 
Fat 33 ± 7*% 34% 20-35% 
*Mean ± standard deviation  
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Table 3 .  Mean daily intakes of selected nutrients. 
Nutrients Mean daily 
intakes 
Range  
Energy (kcal) 1415±477 687-2887 
Carbohydrate (g) 171.11±65.26 58.20-292.38 
Fiber (g)  15.2±7.23 3.76-35.37 
Protein (g) 59.83±21.91 25.97-108.96 
Fat (g) 51.17±18.64 25.52-95.22 
Saturated Fat (g) 15.46±5.63 5.60-30.12 
Trans Fat (g) 2.63±1.13 0.66-5.85 
MUFA (g) 19.77±7.60 7.58-35.06 
PUFA (g) 12.04±5.49 4.73-28.41 
LA (g) 10.78±4.97 3.93-25.20 
AA (g) 0.08±0.04 0.02-0.18 
Estimated total n-6 (g) 10.86±5.00 3.95-25.34 
ALA (g) 0.98±0.45 0.38-2.53 
EPA (g) 0.03±0.03 0-0.15 
DHA (g) 0.06±0.06 0.01-0.34 
Dietary n-3 (g) 1.07±0.51 0.43-2.76 
Estimated total n-3 (diet + 
supplements) (g) 
1.27±0.60 0.43-3.14 
 
Table 4.  Mean n-3 and n-6 levels in breast, plasma, RBCs and diet. 
 Plasma  RBC Intake (g/d)* 
Fatty Acid PL* TG* PL*  
EPA 0.72 (0.41) 0.23 (0.23) 0.63 (0.52) 0.03 (0.03) 
DHA 3.23 (1.00) 0.43 (0.40) 4.12 (1.14) 0.06 (0.06) 
ALA 0.39 (0.52) 0.19 (0.22) 2.54 (0.66) 0.98 (0.45) 
Total n-3 4.04 (1.16) 2.23 (1.50) 5.48 (1.52) 1.27 (0.60) 
AA 10.36 (1.93) 1.55 (0.50) 13.29 (2.07) 0.08 (0.04) 
LA 20.20 (3.34) 20.97 (3.95) 10.13 (1.34) 10.78 (4.97) 
Total n-6 34.06 (3.36) 23.64 (3.85) 27.82 (3.43) 10.86 (5.00) 
n-6:n-3 
Ratio 9.02 (2.59) 12.89 (5.44) 5.42 (1.48) 9.14 (3.35) 
Trans Fatty 
Acids 1.53 (0.46) 1.22 (0.59) 1.99 (0.65) 2.63 (1.13) 
*Mean % (SD) 
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Correlations 
Approximately one third of the subjects were taking n-3 supplements 
(fish oil or flaxseed).  Fish oil usage was positively correlated with total 
estimated n-3 intake (r=0.481, p=0.001) and DHA in RBC PL (r=0.356, 
p=0.026), plasma PL (r=0.356, p=0.026), and plasma TG (r=0.387, p=0.015).    
Similarly, fish oil usage was positively correlated with EPA in RBC PL 
(r=0.514, p=0.001) and plasma PL (r=0.433, p=0.006).  Fish oil was negatively 
correlated with AA in RBC PL (r=-0.510, p=0.001) as well as the n-6:n-3 ratio 
in RBC PL (r=-0.396, p=0.003) and plasma TG (r=-0.426, p=0.007). 
Estimated total n-3 PUFA intake (including both food and supplements) 
was positively correlated with DHA in RBC PL and plasma TG (see table 5).  
The best predictor of DHA levels in RBC and plasma was DHA intake 
(r=0.663, p=<0.001), even though DHA intake was only 0.6 g/d.  Plasma TG 
EPA was also strongly correlated with n-3 intake, while RBC PL AA was 
negatively correlated with n-3 intake.  Other negative correlations of n-3 intake 
were with the n-6:n-3 ratio in RBC PL, plasma PL, and plasma TG.  Dietary n-6 
PUFA intake was positively correlated with DHA and EPA in plasma TG 
(r=0.376, p=0.018; r=0.508, p=0.001, respectively).  The same relationship was 
seen for n-6 LA but not n-6 AA. 
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Table 5.  Correlates with n-3 and n-6 PUFA intake. 
 Correlate Pearson Correlation 
(p=<0.05) 
n-3 PUFA 
Intake 
 
RBC PL DHA 
Plasma TG DHA 
Plasma TG EPA 
RBC PL AA 
RBC PL n-6:n-3 
Plasma PL n-6:n-3 
Plasma TG n-6:n-3 
0.348 
0.532 
0.511 
-0.450 
-0.453 
-0.341 
-0.370 
n-6 PUFA 
Intake 
Plasma TG DHA 
Plasma TG EPA 
0.376 
0.508 
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Chapter 5 
 
Discussion 
 
This observational pilot study provided key analysis of dietary intakes 
and blood biomarkers of LCPUFA status in women who are at high risk for 
breast cancer who were consuming very low amounts of n-3 PUFAs.  RBC and 
plasma LCPUFAs were clearly related to n-3 intake, which confirms previous 
findings (94).  These results validate the use of both the DHQ and RBC analysis 
methods in this population, and will be used in a phase II intervention trial using 
a high-dose n-3 PUFA supplement as a means for breast cancer risk reduction in 
a high risk population of women. 
Mean Gail risk of this sample was 2.7 ± 2.2%, which is greater than 
twice the risk than the average 48 year old woman, who has a 5-year Gail risk of 
1.2% (91) .  Women who know they are at high risk for breast cancer may 
choose to modify lifestyle factors, including diet, to decrease risk.   
Being overweight is a known risk factor for breast cancer(95).  This 
population of women at high risk for breast cancer had a lower incidence of 
obesity and higher incidence of overweight than national estimates, with 34% of 
subjects overweight (BMI 25-29.9) and 15% obese (BMI≥30), compared to 
CDC statistics from 1999-2000 which classify US adults as overweight and 
obese at rates of 25% and 23%, respectively (92).  BMI was negatively 
correlated with DHA and seafood intakes, while energy intake was positively 
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correlated with intakes of n-3 PUFAs, EPA and seafood.  It is interesting to note 
that individuals consuming more energy in conjunction with more n-3 PUFAs 
had a lower body weight.  
Postmenopausal status was correlated with intakes of n-3 and n-6 
PUFAs, LA and trans fatty acids.  Carbohydrate intake was associated with pro-
inflammatory nutrients, including n-6 PUFA, LA, ARA, total PUFA, and trans 
fatty acids.  This may be of concern since inflammation may be associated with 
chronic diseases such as cancer and heart disease(96, 97), which are concerns in 
postmenopausal women(98). 
Mean energy intake was estimated at 1415 calories per day, which is 
approximately 24% lower than the NHANES What We Eat in America 
(WWEIA) 2005-2006 reported food energy for females 40-49 (92).  Similarly, 
mean intakes of macronutrients – carbohydrate, protein and fat – were 23, 21 
and 29% lower than WWEIA 2005-2006.  However, macronutrient distribution 
range was similar to WWEIA (see table 2).  All macronutrients were within the 
Accepted Macronutrient Distribution Ranges (see table 2) (93).  DHA intake 
was low in this population, 33% lower than the WWEIA data from 2005-2006 
for females 40-49 (92).  Total n-3 intake was less related to plasma or RBC total 
n-3 PUFA than plasma and RBC DHA (data not shown).  The strongest 
biomarkers of n-3 intake were plasma TG DHA (r=0.532)  and RBC PL n-6:n-3 
(r=0.453).  Increasing DHA intake using high-dose supplementation could 
significantly decrease this ratio, and potentially decrease the risk of breast 
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cancer.  It is still unknown what level of intake is required to influence the n-
6:n-3 ratio in breast tissue, which is a known risk factor.   It is important to 
know if and when red blood cell (RBC) phospholipid (PL) and plasma PL and 
TAG LCPUFA can be used as an indicator of breast tissue PL and TAG 
LCPUFA.   
One limitation of this study is that the subjects were instructed to 
discontinue use of n-3 PUFA supplements for 3 weeks prior to their clinic visit.  
It is unknown if and when the subjects stopped taking the supplements, but we 
were still able to find an association in RBC and plasma with intake.  Further, 
the response rate for the DHQ was only 58%, which is lower than NCI estimates 
of 70-80% for this survey(88).   Another limitation is underreporting associated 
with the DHQ.  Reported energy intakes ranged from 687-2887 kilocalories per 
day.  Women tend to underreport more than men, and underreporting is more 
common in obese individuals(99).  In a review evaluating the validity of 
reported energy intake, diet history had the least amount of results below the 
acceptable cut-off point (25% of results), while diet records and diet recalls fell 
below the cut-off point 64% and 88% of the time, respectively(99).  Therefore, 
the DHQ appears to be more reliable than diet records or recalls when assessing 
energy intake.   
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Chapter 6 
Summary 
 
The risk of breast cancer is higher in women who have a higher ratio of 
n-6:n-3 LCPUFAs in breast tissue.  Before dietary recommendations can be 
made regarding n-3 PUFAs in relation to breast cancer risk reduction, a less 
invasive biomarker than breast tissue must be identified so that further research 
can be done in larger populations.   
 This observational pilot study compared LCPUFA intake to RBC and 
plasma LCPUFAs in women at high risk for breast cancer.  Women were 
recruited from a high risk breast clinic and asked to fill out DHQ’s and provide 
blood samples for fatty acid analyses.  The mean age of the subjects was 47 ± 
9.9 years, and the mean BMI was 25 ± 4.4.  The mean 5-year Gail risk was 2.7 
± 2.2%.  Twenty-two (48%) of the subjects were premenopausal and 24 (52%) 
were postmenopausal.  Fifteen (33%) were taking an n-3 PUFA supplement 
(fish oil or flaxseed).  Mean intakes were 9.94 ± 4.9 g n-6/d and 1.26 ± 0.6 g n-
3/d, with an n-6:n-3 ratio of approximately 9:1.  Total PL n-6 in RBC and 
plasma was 27.74 ± 3.44% and 33.92 ± 3.72%, respectively.  Total PL n-3 in 
RBC and plasma was 5.59 ± 1.7% and 4.06 ± 1.19%, respectively. RBC PL n-3 
was highly correlated with n-3 intake (r=0.42).   
 Women at the University of Kansas Medical Center Breast Cancer 
Prevention Center consume an n-6:n-3 LCPUFA ratio typical of the US 
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population.  Even though DHA intake was only 0.6 g/d, it was still highly 
correlated with plasma TG DHA (r=0.663, p=<.001).  At low intakes of n-3 
PUFAs, RBC PL n-3s were significantly correlated to dietary n-3, adding to the 
validity of both intake and biomarker.   This study provided key analyses so an 
n-3 PUFA intervention trial can be performed in women at high risk for breast 
cancer.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
30 
 
 
References 
1. Maillard V, Bougnoux P, Ferrari P, et al. N-3 and N-6 fatty acids in 
breast adipose tissue and relative risk of breast cancer in a case-control 
study in Tours, France. Int J Cancer 2002;98(1):78-83. doi: 
10.1002/ijc.10130 [pii]. 
2. Goodstine SL, Zheng T, Holford TR, et al. Dietary (n-3)/(n-6) fatty acid 
ratio: possible relationship to premenopausal but not postmenopausal 
breast cancer risk in U.S. women. J Nutr 2003;133(5):1409-14. 
3. Amiano P, Dorronsoro M, de Renobales M, Ruiz de Gordoa JC, Irigoien 
I. Very-long-chain omega-3 fatty acids as markers for habitual fish 
intake in a population consuming mainly lean fish: the EPIC cohort of 
Gipuzkoa. European Prospective Investigation into Cancer and 
Nutrition. Eur J Clin Nutr 2001;55(10):827-32. doi: 
10.1038/sj.ejcn.1601242 [doi]. 
4. Maclean CH, Newberry SJ, Mojica WA, et al. Effects of omega-3 fatty 
acids on cancer. Evid Rep Technol Assess (Summ) 2005(113):1-4. 
5. Berquin IM, Edwards IJ, Chen YQ. Multi-targeted therapy of cancer by 
omega-3 fatty acids. Cancer Lett 2008;269(2):363-77. doi: S0304-
3835(08)00256-5 [pii] 
10.1016/j.canlet.2008.03.044 [doi]. 
6. Bagga D, Anders KH, Wang HJ, Glaspy JA. Long-chain n-3-to-n-6 
polyunsaturated fatty acid ratios in breast adipose tissue from women 
with and without breast cancer. Nutr Cancer 2002;42(2):180-5. 
7. Simopoulos AP. Essential fatty acids in health and chronic disease. Am J 
Clin Nutr 1999;70(3 Suppl):560S-9S. 
8. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, 
omega-3 fatty acids, and cardiovascular disease. Circulation 
2002;106(21):2747-57. 
9. Liu G, Bibus DM, Bode AM, Ma WY, Holman RT, Dong Z. Omega 3 
but not omega 6 fatty acids inhibit AP-1 activity and cell transformation 
in JB6 cells. Proc Natl Acad Sci U S A 2001;98(13):7510-5. doi: 
10.1073/pnas.131195198 [doi] 
98/13/7510 [pii]. 
10. Terry PD, Terry JB, Rohan TE. Long-chain (n-3) fatty acid intake and 
risk of cancers of the breast and the prostate: recent epidemiological 
studies, biological mechanisms, and directions for future research. J Nutr 
2004;134(12 Suppl):3412S-20S. doi: 134/12/3412S [pii]. 
11. Shao Y, Pardini L, Pardini RS. Dietary menhaden oil enhances 
mitomycin C antitumor activity toward human mammary carcinoma 
MX-1. Lipids 1995;30(11):1035-45. 
  
31 
 
12. Yam D, Eliraz A, Berry EM. Diet and disease--the Israeli paradox: 
possible dangers of a high omega-6 polyunsaturated fatty acid diet. Isr J 
Med Sci 1996;32(11):1134-43. 
13. Brenna JT. Efficiency of conversion of alpha-linolenic acid to long chain 
n-3 fatty acids in man. Curr Opin Clin Nutr Metab Care 2002;5(2):127-
32. 
14. Brenna JT, Salem N, Jr., Sinclair AJ, Cunnane SC. alpha-Linolenic acid 
supplementation and conversion to n-3 long-chain polyunsaturated fatty 
acids in humans. Prostaglandins Leukot Essent Fatty Acids 2009;80(2-
3):85-91. doi: S0952-3278(09)00016-7 [pii] 
10.1016/j.plefa.2009.01.004 [doi]. 
15. Wijendran V, Hayes KC. Dietary n-6 and n-3 fatty acid balance and 
cardiovascular health. Annu Rev Nutr 2004;24:597-615. doi: 
10.1146/annurev.nutr.24.012003.132106 [doi]. 
16. Wen B, Deutsch E, Opolon P, et al. n-3 polyunsaturated fatty acids 
decrease mucosal/epidermal reactions and enhance antitumour effect of 
ionising radiation with inhibition of tumour angiogenesis. Br J Cancer 
2003;89(6):1102-7. doi: 10.1038/sj.bjc.6601136 [doi] 
6601136 [pii]. 
17. Tsuzuki T, Kawakami Y. Tumor angiogenesis suppression by alpha-
eleostearic acid, a linolenic acid isomer with a conjugated triene system, 
via peroxisome proliferator-activated receptor gamma. Carcinogenesis 
2008;29(4):797-806. doi: bgm298 [pii] 
10.1093/carcin/bgm298 [doi]. 
18. McCarty MF. Fish oil may impede tumour angiogenesis and 
invasiveness by down-regulating protein kinase C and modulating 
eicosanoid production. Med Hypotheses 1996;46(2):107-15. doi: S0306-
9877(96)90009-2 [pii]. 
19. Form DM, Auerbach R. PGE2 and angiogenesis. Proc Soc Exp Biol 
Med 1983;172(2):214-8. 
20. Connolly JM, Rose DP. Enhanced angiogenesis and growth of 12-
lipoxygenase gene-transfected MCF-7 human breast cancer cells in 
athymic nude mice. Cancer Lett 1998;132(1-2):107-12. doi: S0304-
3835(98)00171-2 [pii]. 
21. Bing RJ, Miyataka M, Rich KA, et al. Nitric oxide, prostanoids, 
cyclooxygenase, and angiogenesis in colon and breast cancer. Clin 
Cancer Res 2001;7(11):3385-92. 
22. Dabrosin C, Chen J, Wang L, Thompson LU. Flaxseed inhibits 
metastasis and decreases extracellular vascular endothelial growth factor 
in human breast cancer xenografts. Cancer Lett 2002;185(1):31-7. doi: 
S0304383502002392 [pii]. 
23. Rose DP, Connolly JM. Effects of fatty acids and inhibitors of 
eicosanoid synthesis on the growth of a human breast cancer cell line in 
culture. Cancer Res 1990;50(22):7139-44. 
  
32 
 
24. Noguchi M, Minami M, Yagasaki R, et al. Chemoprevention of DMBA-
induced mammary carcinogenesis in rats by low-dose EPA and DHA. Br 
J Cancer 1997;75(3):348-53. 
25. Hardman WE, Avula CP, Fernandes G, Cameron IL. Three percent 
dietary fish oil concentrate increased efficacy of doxorubicin against 
MDA-MB 231 breast cancer xenografts. Clin Cancer Res 
2001;7(7):2041-9. 
26. Barascu A, Besson P, Le Floch O, Bougnoux P, Jourdan ML. CDK1-
cyclin B1 mediates the inhibition of proliferation induced by omega-3 
fatty acids in MDA-MB-231 breast cancer cells. Int J Biochem Cell Biol 
2006;38(2):196-208. doi: S1357-2725(05)00268-2 [pii] 
10.1016/j.biocel.2005.08.015 [doi]. 
27. Chamras H, Ardashian A, Heber D, Glaspy JA. Fatty acid modulation of 
MCF-7 human breast cancer cell proliferation, apoptosis and 
differentiation. J Nutr Biochem 2002;13(12):711-6. doi: 
S0955286302002309 [pii]. 
28. Menendez JA, Vazquez-Martin A, Ropero S, Colomer R, Lupu R. HER2 
(erbB-2)-targeted effects of the omega-3 polyunsaturated fatty acid, 
alpha-linolenic acid (ALA; 18:3n-3), in breast cancer cells: the "fat 
features" of the "Mediterranean diet" as an "anti-HER2 cocktail". Clin 
Transl Oncol 2006;8(11):812-20. doi: 932 [pii]. 
29. Jump DB, Clarke SD, Thelen A, Liimatta M, Ren B, Badin MV. Dietary 
fat, genes, and human health. Adv Exp Med Biol 1997;422:167-76. 
30. Collett ED, Davidson LA, Fan YY, Lupton JR, Chapkin RS. n-6 and n-3 
polyunsaturated fatty acids differentially modulate oncogenic Ras 
activation in colonocytes. Am J Physiol Cell Physiol 
2001;280(5):C1066-75. 
31. Sessler AM, Ntambi JM. Polyunsaturated fatty acid regulation of gene 
expression. J Nutr 1998;128(6):923-6. 
32. El-Sohemy A, Archer MC. Regulation of mevalonate synthesis in low 
density lipoprotein receptor knockout mice fed n-3 or n-6 
polyunsaturated fatty acids. Lipids 1999;34(10):1037-43. 
33. Zand H, Rhimipour A, Bakhshayesh M, Shafiee M, Nour Mohammadi I, 
Salimi S. Involvement of PPAR-gamma and p53 in DHA-induced 
apoptosis in Reh cells. Mol Cell Biochem 2007;304(1-2):71-7. doi: 
10.1007/s11010-007-9487-5 [doi]. 
34. Schwartz SA, Hernandez A, Mark Evers B. The role of NF-
kappaB/IkappaB proteins in cancer: implications for novel treatment 
strategies. Surg Oncol 1999;8(3):143-53. doi: S0960-7404(00)00012-8 
[pii]. 
35. Sun H, Berquin IM, Owens RT, O'Flaherty JT, Edwards IJ. Peroxisome 
proliferator-activated receptor gamma-mediated up-regulation of 
syndecan-1 by n-3 fatty acids promotes apoptosis of human breast 
cancer cells. Cancer Res 2008;68(8):2912-9. doi: 68/8/2912 [pii] 
  
33 
 
10.1158/0008-5472.CAN-07-2305 [doi]. 
36. Stillwell W, Wassall SR. Docosahexaenoic acid: membrane properties 
of a unique fatty acid. Chem Phys Lipids 2003;126(1):1-27. doi: 
S0009308403001014 [pii]. 
37. Bougnoux P, Hajjaji N, Couet C. The lipidome as a composite 
biomarker of the modifiable part of the risk of breast cancer. 
Prostaglandins Leukot Essent Fatty Acids 2008;79(3-5):93-6. doi: 
S0952-3278(08)00122-1 [pii] 
10.1016/j.plefa.2008.09.004 [doi]. 
38. Kamano K, Okuyama H, Konishi R, Nagasawa H. Effects of a high-
linoleate and a high-alpha-linolenate diet on spontaneous mammary 
tumourigenesis in mice. Anticancer Res 1989;9(6):1903-8. 
39. Rose DP, Connolly JM. Effects of dietary omega-3 fatty acids on human 
breast cancer growth and metastases in nude mice. J Natl Cancer Inst 
1993;85(21):1743-7. 
40. Chen J, Stavro PM, Thompson LU. Dietary flaxseed inhibits human 
breast cancer growth and metastasis and downregulates expression of 
insulin-like growth factor and epidermal growth factor receptor. Nutr 
Cancer 2002;43(2):187-92. 
41. Fritsche KL, Johnston PV. Effect of dietary alpha-linolenic acid on 
growth, metastasis, fatty acid profile and prostaglandin production of 
two murine mammary adenocarcinomas. J Nutr 1990;120(12):1601-9. 
42. Jurkowski JJ, Cave WT, Jr. Dietary effects of menhaden oil on the 
growth and membrane lipid composition of rat mammary tumors. J Natl 
Cancer Inst 1985;74(5):1145-50. 
43. Hardman WE. Dietary canola oil suppressed growth of implanted MDA-
MB 231 human breast tumors in nude mice. Nutr Cancer 
2007;57(2):177-83. doi: 10.1080/01635580701277445 [doi]. 
44. Abou-el-Ela SH, Prasse KW, Farrell RL, Carroll RW, Wade AE, Bunce 
OR. Effects of D,L-2-difluoromethylornithine and indomethacin on 
mammary tumor promotion in rats fed high n-3 and/or n-6 fat diets. 
Cancer Res 1989;49(6):1434-40. 
45. Jourdan ML, Maheo K, Barascu A, et al. Increased BRCA1 protein in 
mammary tumours of rats fed marine omega-3 fatty acids. Oncol Rep 
2007;17(4):713-9. 
46. Cohen LA, Thompson DO, Choi K, Karmali RA, Rose DP. Dietary fat 
and mammary cancer. II. Modulation of serum and tumor lipid 
composition and tumor prostaglandins by different dietary fats: 
association with tumor incidence patterns. J Natl Cancer Inst 
1986;77(1):43-51. 
47. Badawi AF, El-Sohemy A, Stephen LL, Ghoshal AK, Archer MC. The 
effect of dietary n-3 and n-6 polyunsaturated fatty acids on the 
expression of cyclooxygenase 1 and 2 and levels of p21ras in rat 
mammary glands. Carcinogenesis 1998;19(5):905-10. 
  
34 
 
48. Chen J, Hui E, Ip T, Thompson LU. Dietary flaxseed enhances the 
inhibitory effect of tamoxifen on the growth of estrogen-dependent 
human breast cancer (mcf-7) in nude mice. Clin Cancer Res 
2004;10(22):7703-11. doi: 10/22/7703 [pii] 
10.1158/1078-0432.CCR-04-1130 [doi]. 
49. Kimura Y. Carp oil or oleic acid, but not linoleic acid or linolenic acid, 
inhibits tumor growth and metastasis in Lewis lung carcinoma-bearing 
mice. J Nutr 2002;132(7):2069-75. 
50. Freudenheim JL, Marshall JR. The problem of profound 
mismeasurement and the power of epidemiological studies of diet and 
cancer. Nutr Cancer 1988;11(4):243-50. 
51. Bingham SA, Luben R, Welch A, Wareham N, Khaw KT, Day N. Are 
imprecise methods obscuring a relation between fat and breast cancer? 
Lancet 2003;362(9379):212-4. doi: S0140-6736(03)13913-X [pii] 
10.1016/S0140-6736(03)13913-X [doi]. 
52. Thiebaut AC, Chajes V, Gerber M, et al. Dietary intakes of omega-6 and 
omega-3 polyunsaturated fatty acids and the risk of breast cancer. Int J 
Cancer 2009;124(4):924-31. doi: 10.1002/ijc.23980 [doi]. 
53. Simonsen N, van't Veer P, Strain JJ, et al. Adipose tissue omega-3 and 
omega-6 fatty acid content and breast cancer in the EURAMIC study. 
European Community Multicenter Study on Antioxidants, Myocardial 
Infarction, and Breast Cancer. Am J Epidemiol 1998;147(4):342-52. 
54. Stripp C, Overvad K, Christensen J, et al. Fish intake is positively 
associated with breast cancer incidence rate. J Nutr 2003;133(11):3664-
9. 
55. Welch AA, Lund E, Amiano P, et al. Variability of fish consumption 
within the 10 European countries participating in the European 
Investigation into Cancer and Nutrition (EPIC) study. Public Health 
Nutr 2002;5(6B):1273-85. doi: 10.1079/PHN2002404 [doi] 
S1368980002001453 [pii]. 
56. Pala V, Krogh V, Muti P, et al. Erythrocyte membrane fatty acids and 
subsequent breast cancer: a prospective Italian study. J Natl Cancer Inst 
2001;93(14):1088-95. 
57. Duncan AM. The role of nutrition in the prevention of breast cancer. 
AACN Clin Issues 2004;15(1):119-35. doi: 00044067-200401000-
00011 [pii]. 
58. Caygill CP, Charlett A, Hill MJ. Fat, fish, fish oil and cancer. Br J 
Cancer 1996;74(1):159-64. 
59. Voorrips LE, Brants HA, Kardinaal AF, Hiddink GJ, van den Brandt 
PA, Goldbohm RA. Intake of conjugated linoleic acid, fat, and other 
fatty acids in relation to postmenopausal breast cancer: the Netherlands 
Cohort Study on Diet and Cancer. Am J Clin Nutr 2002;76(4):873-82. 
  
35 
 
60. Weisburger JH. Approaches for chronic disease prevention based on 
current understanding of underlying mechanisms. Am J Clin Nutr 
2000;71(6 Suppl):1710S-4S; discussion 5S-9S. 
61. Kaizer L, Boyd NF, Kriukov V, Tritchler D. Fish consumption and 
breast cancer risk: an ecological study. Nutr Cancer 1989;12(1):61-8. 
62. Mozaffarian D, Pischon T, Hankinson SE, et al. Dietary intake of trans 
fatty acids and systemic inflammation in women. Am J Clin Nutr 
2004;79(4):606-12. 
63. Chung H, Nettleton JA, Lemaitre RN, et al. Frequency and type of 
seafood consumed influence plasma (n-3) fatty acid concentrations. J 
Nutr 2008;138(12):2422-7. doi: 138/12/2422 [pii] 
10.3945/jn.108.089631 [doi]. 
64. Wynder EL, Cohen LA, Muscat JE, Winters B, Dwyer JT, Blackburn G. 
Breast cancer: weighing the evidence for a promoting role of dietary fat. 
J Natl Cancer Inst 1997;89(11):766-75. 
65. Thiebaut AC, Kipnis V, Chang SC, et al. Dietary fat and 
postmenopausal invasive breast cancer in the National Institutes of 
Health-AARP Diet and Health Study cohort. J Natl Cancer Inst 
2007;99(6):451-62. doi: 99/6/451 [pii] 
10.1093/jnci/djk094 [doi]. 
66. Holmes MD, Hunter DJ, Colditz GA, et al. Association of dietary intake 
of fat and fatty acids with risk of breast cancer. JAMA 
1999;281(10):914-20. doi: joc81342 [pii]. 
67. Hunter DJ, Spiegelman D, Adami HO, et al. Cohort studies of fat intake 
and the risk of breast cancer--a pooled analysis. N Engl J Med 
1996;334(6):356-61. 
68. Hursting SD, Thornquist M, Henderson MM. Types of dietary fat and 
the incidence of cancer at five sites. Prev Med 1990;19(3):242-53. 
69. Boyd NF, Stone J, Vogt KN, Connelly BS, Martin LJ, Minkin S. Dietary 
fat and breast cancer risk revisited: a meta-analysis of the published 
literature. Br J Cancer 2003;89(9):1672-85. doi: 10.1038/sj.bjc.6601314 
[doi] 
6601314 [pii]. 
70. Vatten LJ, Solvoll K, Loken EB. Frequency of meat and fish intake and 
risk of breast cancer in a prospective study of 14,500 Norwegian 
women. Int J Cancer 1990;46(1):12-5. 
71. Menotti A, Kromhout D, Blackburn H, Fidanza F, Buzina R, Nissinen 
A. Food intake patterns and 25-year mortality from coronary heart 
disease: cross-cultural correlations in the Seven Countries Study. The 
Seven Countries Study Research Group. Eur J Epidemiol 
1999;15(6):507-15. 
72. Kim EH, Willett WC, Colditz GA, et al. Dietary fat and risk of 
postmenopausal breast cancer in a 20-year follow-up. Am J Epidemiol 
2006;164(10):990-7. doi: kwj309 [pii] 
  
36 
 
10.1093/aje/kwj309 [doi]. 
73. Holmes MD, Colditz GA, Hunter DJ, et al. Meat, fish and egg intake 
and risk of breast cancer. Int J Cancer 2003;104(2):221-7. doi: 
10.1002/ijc.10910 [doi]. 
74. Frazier AL, Ryan CT, Rockett H, Willett WC, Colditz GA. Adolescent 
diet and risk of breast cancer. Breast Cancer Res 2003;5(3):R59-64. doi: 
10.1186/bcr600 [doi]. 
75. Cho E, Spiegelman D, Hunter DJ, et al. Premenopausal fat intake and 
risk of breast cancer. J Natl Cancer Inst 2003;95(14):1079-85. 
76. Ziegler RG, Hoover RN, Pike MC, et al. Migration patterns and breast 
cancer risk in Asian-American women. J Natl Cancer Inst 
1993;85(22):1819-27. 
77. Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE, Mack TM. 
Cancers of the prostate and breast among Japanese and white 
immigrants in Los Angeles County. Br J Cancer 1991;63(6):963-6. 
78. Toniolo P, Riboli E, Shore RE, Pasternack BS. Consumption of meat, 
animal products, protein, and fat and risk of breast cancer: a prospective 
cohort study in New York. Epidemiology 1994;5(4):391-7. 
79. Howe GR, Hirohata T, Hislop TG, et al. Dietary factors and risk of 
breast cancer: combined analysis of 12 case-control studies. J Natl 
Cancer Inst 1990;82(7):561-9. 
80. Rissanen H, Knekt P, Jarvinen R, Salminen I, Hakulinen T. Serum fatty 
acids and breast cancer incidence. Nutr Cancer 2003;45(2):168-75. doi: 
10.1207/S15327914NC4502_05 [doi]. 
81. Shannon J, King IB, Moshofsky R, et al. Erythrocyte fatty acids and 
breast cancer risk: a case-control study in Shanghai, China. Am J Clin 
Nutr 2007;85(4):1090-7. doi: 85/4/1090 [pii]. 
82. Kim J, Lim SY, Shin A, et al. Fatty fish and fish omega-3 fatty acid 
intakes decrease the breast cancer risk: a case-control study. BMC 
Cancer 2009;9:216. doi: 1471-2407-9-216 [pii] 
10.1186/1471-2407-9-216 [doi]. 
83. Wang J, John EM, Horn-Ross PL, Ingles SA. Dietary fat, cooking fat, 
and breast cancer risk in a multiethnic population. Nutr Cancer 
2008;60(4):492-504. doi: 794508066 [pii] 
10.1080/01635580801956485 [doi]. 
84. Trichopoulou A, Katsouyanni K, Stuver S, et al. Consumption of olive 
oil and specific food groups in relation to breast cancer risk in Greece. J 
Natl Cancer Inst 1995;87(2):110-6. 
85. Martin-Moreno JM, Willett WC, Gorgojo L, et al. Dietary fat, olive oil 
intake and breast cancer risk. Int J Cancer 1994;58(6):774-80. 
86. la Vecchia C, Negri E, Franceschi S, Decarli A, Giacosa A, Lipworth L. 
Olive oil, other dietary fats, and the risk of breast cancer (Italy). Cancer 
Causes Control 1995;6(6):545-50. 
  
37 
 
87. Thompson FE, Subar AF, Brown CC, et al. Cognitive research enhances 
accuracy of food frequency questionnaire reports: results of an 
experimental validation study. J Am Diet Assoc 2002;102(2):212-25. 
88. Subar AF, Thompson FE, Kipnis V, et al. Comparative validation of the 
Block, Willett, and National Cancer Institute food frequency 
questionnaires : the Eating at America's Table Study. Am J Epidemiol 
2001;154(12):1089-99. 
89. Schatzkin A, Kipnis V, Carroll RJ, et al. A comparison of a food 
frequency questionnaire with a 24-hour recall for use in an 
epidemiological cohort study: results from the biomarker-based 
Observing Protein and Energy Nutrition (OPEN) study. Int J Epidemiol 
2003;32(6):1054-62. 
90. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation 
and purification of total lipides from animal tissues. J Biol Chem 
1957;226(1):497-509. 
91. Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA. Validation 
of the Gail et al. model of breast cancer risk prediction and implications 
for chemoprevention. J Natl Cancer Inst 2001;93(5):358-66. 
92. Dwyer J, Picciano MF, Raiten DJ. Estimation of usual intakes: What We 
Eat in America-NHANES. J Nutr 2003;133(2):609S-23S. 
93. Barr SI, Murphy SP, Agurs-Collins TD, Poos MI. Planning diets for 
individuals using the dietary reference intakes. Nutr Rev 
2003;61(10):352-60. 
94. Baylin A, Campos H. The use of fatty acid biomarkers to reflect dietary 
intake. Curr Opin Lipidol 2006;17(1):22-7. doi: 00041433-200602000-
00005 [pii]. 
95. Nkondjock A, Ghadirian P. [Risk factors and risk reduction of breast 
cancer]. Med Sci (Paris) 2005;21(2):175-80. doi: 00/00/06/D2/ [pii]. 
96. Balkwill F, Mantovani A. Cancer and inflammation: implications for 
pharmacology and therapeutics. Clin Pharmacol Ther 2010;87(4):401-6. 
doi: clpt2009312 [pii] 
10.1038/clpt.2009.312 [doi]. 
97. Corson MA. Emerging inflammatory markers for assessing coronary 
heart disease risk. Curr Cardiol Rep 2009;11(6):452-9. 
98. Rees M, Stevenson J. Primary prevention of coronary heart disease in 
women. Menopause Int 2008;14(1):40-5. doi: 10.1258/mi.2007.007037 
[doi]. 
99. Black AE, Goldberg GR, Jebb SA, Livingstone MB, Cole TJ, Prentice 
AM. Critical evaluation of energy intake data using fundamental 
principles of energy physiology: 2. Evaluating the results of published 
surveys. Eur J Clin Nutr 1991;45(12):583-99. 
 
 
